Table 1.
Characteristics (n (%) or mean ± SD) of participants at study entry and during 12-month follow-up.
| At Study Entry | IPF Patients during 1-Year Follow-Up | |||||
|---|---|---|---|---|---|---|
| Control (n = 32) | IPF (n = 32) | p-Value | Progressor (n = 18) | Stable (n = 13) | p-Value | |
| Age | 71.1 ± 5.17 | 71.6 ± 7.01 | 0.344 | 71.8 ± 5.99 | 70.7 ± 8.39 | 0.679 |
| Males, n (%) | 13 (40.6%) | 23 (71.9%) | 0.023 | 14 (77.8%) | 9 (69.2%) | 0.689 |
| Smoking status | 0.445 | 0.784 | ||||
| Former smoker | 21 (65.6%) | 25 (78.1%) | 15 (83.3%) | 10 (76.9%) | ||
| Never smoker | 6 (18.8%) | 5 (15.6%) | 3 (16.7%) | 2 (15.4%) | ||
| Current smoker | 5 (15.6%) | 2 (6.25%) | 0 (0.00%) | 1 (7.69%) | ||
| BMI, Kg/m2 | 25.3 (3.5) | 29.2 (8.72) | 0.037 | 29.7 (10.0) | 28.5 (6.81) | 0.721 |
| FVC, % ref. | 106 (20.9) | 69.8 (18.3) | <0.001 | 60.3 (10.8) | 79.5 (16.8) | 0.002 |
| FEV1, % ref. | 96.4 (17.2) | 77.0 (16.7) | <0.001 | 69.3 (11.7) | 85.3 (16.8) | 0.008 |
| FEV1/FVC, % | 98.0 (8.27) | 81.1 (5.80) | <0.001 | 83.1 (5.38) | 78.9 (5.63) | 0.055 |
| DLCO, % ref. | NA | 46.9 (16.8) | 41.9 (14.7) | 53.9 (17.9) | 0.063 | |
| Antifibrotic before *, n (%) | <0.001 | 1.000 | ||||
| Yes | 0 (0%) | 12 (37.5%) | 7 (38.9%) | 5 (38.5%) | ||
| Antifibrotic after *, n (%) | <0.001 | 0.497 | ||||
| Yes | 0 (0%) | 30 (93.8%) | 16 (88.9%) | 13 (100%) | ||
| Antifibrotic drug, n (%) | <0.001 | 0.348 | ||||
| Nintedanib | 0 (0%) | 22 (73.3%) | 13 (72.2%) | 8 (61.5%) | ||
| Pirfenidone | 0 (0%) | 8 (26.7%) | 3 (16.7%) | 5 (38.5%) | ||
| Death, n (%) | 1.000 | 0.025 | ||||
| Yes | 0 (0%) | 0 (0%) | 7 (38.9%) | 0 (0%) | ||
NA = Not available information; BMI = Body mass index; FVC = Forced Vital Capacity; FEV1 = Forced expiratory capacity 1 s; DLCO = Single breath carbon monoxide diffusing capacity; Antifibrotic before * = Antifibrotic treatment before recruitment; Antifibrotic after * = Antifibrotic treatment after recruitment.